How Common Is a False-Positive TB Blood Test?

False-positive results on TB blood tests are surprisingly common, especially in people who are at low risk of actually having tuberculosis. In low-prevalence settings like the United States, the majority of positive results in routine screening turn out to be false alarms. The CDC itself warns that in healthy people with a low likelihood of TB infection, “a false-positive result is more likely” than a true one, and recommends reassessing and potentially retesting before acting on a single positive result. The picture gets more complicated with serial testing, borderline values, and specific populations, all of which shift the odds in ways worth understanding.

How Often a Single Test Comes Back Falsely Positive

TB blood tests, known as interferon-gamma release assays (IGRAs), work by measuring your immune system’s response to proteins specific to the TB bacterium. The two main versions are the QuantiFERON-TB Gold Plus and the T-SPOT.TB. Both are generally more specific than the older tuberculin skin test, but “more specific” does not mean “always right.”

In a study tracking 557 people who had tested negative on the skin test, 80 had a positive QuantiFERON result over a follow-up period of up to seven years. Of those 80, only 10 stayed positive the following year, and 9 of those 10 reverted to negative within three years.¹ In other words, most of those initial positives were transient blips rather than signals of real infection.

The practical question for you is not just the test’s raw specificity in a controlled study but what your particular positive result actually means. That depends on your personal risk profile, which brings us to the role of prevalence.

Why Your Risk Level Changes Everything

A test’s specificity tells you how well it identifies people who do not have TB. Even a specificity above 95% sounds reassuring until you consider what happens when you screen a large group of people who almost certainly don’t have TB. In that scenario, the small percentage of false positives can easily outnumber the true positives, because there are so few true cases to find.

One modeling study estimated the positive predictive value of an IGRA for future progression to active TB at just 1.3%.² That means roughly 99 out of every 100 people who tested positive would never go on to develop TB disease. Separately, a study comparing test performance across different prevalence settings found that in a country like the United States, where latent TB prevalence sits around 5%, the trade-off was about 37.7 false positives for every true positive identified when using the T-SPOT.TB.³ In a high-prevalence country like Ivory Coast, that ratio dropped to roughly 2.5 false positives per true positive.

The CDC’s 2010 guidelines make this explicit: in healthy people with a low likelihood of TB infection, a single positive IGRA “should not be taken as reliable evidence of M. tuberculosis infection,” and confirmatory steps should be considered.⁴ If you live in a low-burden country, have no known TB contacts, and are otherwise healthy, the math strongly favors the possibility that your positive result is a false alarm.

Serial Testing Makes the Problem Worse

Many people, particularly healthcare workers, are tested for TB not once but repeatedly over the course of their careers. Each round of testing carries its own small chance of a false positive, and those chances accumulate. A Markov modeling study projected what happens when you test a population annually using QuantiFERON: after ten years, about 24.6% of people were expected to have received at least one false-positive result, compared with just 0.85% true positives. That works out to roughly 29 false positives for every real TB infection detected.⁵

The cumulative study mentioned earlier saw the same pattern play out in real data: the number of people with at least one positive QuantiFERON result climbed steadily year over year, reaching about 27% after seven annual rounds of screening.¹ With TB transmission declining in the United States, large-scale screening programs aimed at low-risk healthcare workers have increasingly become generators of false-positive results rather than detectors of actual infection.⁶

The Borderline Zone

The QuantiFERON test uses a numerical cutoff to divide positive from negative results: 0.35 IU/mL of interferon-gamma. If your value lands at 0.36, you are officially positive. If it comes in at 0.34, you are negative. That binary split papers over the reality that results near the cutoff are highly unstable.

A large study of over 40,000 tests found that about 9% of all results fell within a borderline range. Among people whose initial result was just above the cutoff (between 0.35 and 0.99 IU/mL), 42.5% were negative on follow-up, and none developed active TB.⁷ A separate retrospective analysis of borderline-positive results (0.35 to 0.70 IU/mL) found that 52.2% reverted to negative, with no cases of active TB among those who reverted.⁸

If your QuantiFERON value is just barely positive, the odds that it reflects a true latent infection are considerably lower than if the value is high. Some researchers have argued for raising the cutoff or introducing a formal borderline zone to reduce unnecessary treatment. One study noted that raising the cutoff to 0.7 IU/mL reduced the number of positive results that appeared to be false positives related to blood-handling variability.⁹ As it stands, though, the 0.35 cutoff remains standard, and clinicians are left to interpret borderline results using their judgment about your risk profile.

What Causes a False Positive

Several biological and practical factors can push an IGRA result above the cutoff without real TB infection being present.

Environmental mycobacteria: The TB blood test targets antigens that are fairly specific to the Mycobacterium tuberculosis complex, but they are not perfectly unique. Some environmental mycobacteria, which live in soil and water and are generally harmless, can cross-react with the test. One documented case linked a false-positive QuantiFERON to Mycobacterium gordonae, a species commonly found in tap water.¹⁰
Blood handling and agitation: The QuantiFERON test requires blood to be collected in special tubes that must be handled within specific time and temperature constraints. The way blood is drawn and transferred matters. Research has shown that additional agitation from transferring blood between tubes increased the frequency of positive results compared with drawing directly into the assay tubes.⁹
Within-person immune variability: Your immune system’s interferon-gamma production is not a fixed number. Day-to-day fluctuations in immune activity, recent infections, or even the time of day can shift your result across the cutoff. This is part of why borderline results are so unreliable on retest.

None of these causes involve TB. Yet each can produce a result that looks exactly like latent TB infection on paper.

How TB Blood Tests Compare to the Skin Test

The older tuberculin skin test (TST) has its own false-positive problem, and it is arguably worse. The TST uses a purified protein derivative that shares antigens with the BCG vaccine, which is given to children in much of the world. If you were vaccinated with BCG as a child, a skin test can register positive for years or even decades afterward, even though you were never infected with TB.¹¹

IGRAs were developed in part to solve this problem. The antigens they target (ESAT-6 and CFP-10) are present in the TB bacterium but absent from BCG vaccine strains, so BCG vaccination does not cause IGRA false positives. This has been confirmed across multiple populations, including in a study of HIV-infected individuals from a low-prevalence country where the skin test was significantly affected by prior BCG vaccination but the IGRA was not.¹² A comparison of both tests in TB contacts found 94% agreement between the two methods and confirmed that the IGRA-specific blood test was not influenced by vaccination status.¹³

A cost analysis put this advantage in concrete financial terms: per 10,000 tests performed, the estimated cost of treating people with false-positive results was about $194,000 for skin tests but only about $9,500 for IGRAs.¹⁴ That roughly 20-fold difference reflects the much higher false-positive rate of the skin test, particularly in BCG-vaccinated populations. So while IGRA false positives are real, the blood test is still a substantial improvement over the alternative for many people.

Children and Immunocompromised People

Data on false-positive IGRAs in children are thinner than in adults, and the studies that exist suggest the problem is relatively uncommon but not absent. A case series from a hospital in Spain identified 7 false-positive QuantiFERON results out of 737 tests in children over a five-year period. Several of those occurred in children with chronic medical conditions, and one was linked to a non-TB mycobacterial infection.¹⁵ A clinical guideline from the American Academy of Pediatrics noted that the strongest and most consistent finding across studies is that IGRAs have higher specificity than the skin test for children, particularly in low-burden settings and among BCG-vaccinated kids.¹⁶

For people with weakened immune systems, the problem flips: rather than false positives, the bigger concern is indeterminate or false-negative results. A study of immunocompromised patients found that 13% had indeterminate QuantiFERON results, and these were significantly more common in people receiving immunosuppressive treatment, especially those with low lymphocyte counts.¹⁷ An indeterminate result is not the same as a false positive; it means the test could not produce a reliable answer at all. If you are on medications that suppress your immune system, the test may simply fail rather than give you a wrong answer.

Differences Between the Two Main Blood Tests

QuantiFERON and T-SPOT.TB use different laboratory methods to measure the same basic thing: your T cells’ reaction to TB-specific antigens. A systematic review and meta-analysis comparing the newer QuantiFERON-TB Gold Plus with the older QuantiFERON-GIT and the T-SPOT.TB found no statistically significant differences in specificity among the tests in populations with very low risk of TB exposure.¹⁸ In other words, when it comes to false positives, neither blood test has a clear advantage over the other in low-risk groups.

Where the tests diverge somewhat is in sensitivity for active TB. One study found sensitivities of about 85% for QuantiFERON-TB Gold Plus and about 90% for T-SPOT.TB, with specificities of roughly 62% and 52% respectively.¹⁹ The lower specificity of T-SPOT.TB in that context means more false positives when used in active TB diagnosis, though that is a different clinical scenario from screening for latent infection. Another comparison of the two assays in febrile patients found similar diagnostic accuracy overall.²⁰ For routine screening purposes, the choice between the two is unlikely to meaningfully change your risk of getting a false-positive result.

What Happens After a Positive Result

If you get a positive TB blood test, the standard next step is a chest X-ray and clinical evaluation. If the X-ray is normal and you have no symptoms, you are generally classified as having latent TB infection and offered preventive treatment, which typically involves months of antibiotics. The problem is that false-positive results send people down this same treatment pathway unnecessarily.

Preventive therapy for latent TB is not trivial. Regimens can run from three to nine months and carry risks of liver toxicity and other side effects. For someone who never actually had TB, every one of those risks is pure downside. The cost analysis mentioned earlier estimated that among every 10,000 IGRAs performed in a general population, about $9,500 would go toward treating people whose positive results were false.¹⁴ At the individual level, the burden is real: months of medication, follow-up blood work to monitor your liver, and the psychological weight of being told you have a TB infection you do not have.

The CDC guidance offers a practical escape valve. If you are low-risk and get a single positive result, you and your doctor can reasonably decide to repeat the test before starting treatment. Many borderline-positive results revert to negative on retest, and the evidence suggests those reversions are not associated with progression to active TB.⁸ Some clinicians also use risk-stratified interpretation: if your value is just barely over the 0.35 cutoff and you have no risk factors, they may treat it differently than a result of 4.0 IU/mL in someone who recently arrived from a high-burden country.

The Screening Paradox for Healthcare Workers

Healthcare workers in the United States have been subject to TB screening requirements for decades, often annually. When TB was more common in hospitals, this made sense: the yield of real infections justified the testing. But as TB transmission in U.S. healthcare settings has plummeted, the math has shifted. In a population where almost nobody has TB, even a highly specific test will produce more false positives than true ones.⁶

This is not a hypothetical. The Markov model projecting 29 false positives for every true positive over ten years was specifically modeling the kind of annual screening that healthcare workers undergo.⁵ Partly because of evidence like this, guidelines have evolved. The CDC now recommends that healthcare workers in settings without known TB exposure undergo baseline testing when hired but not necessarily repeated annual testing. Symptom-based screening and risk assessment have replaced rote annual blood draws in many hospitals.

If you are a healthcare worker who recently got a positive result during routine screening, the context matters more than the number. Were you exposed to a known TB case? Have you traveled to or lived in a country where TB is common? If the answer to both is no, the statistical likelihood that your positive result is a false alarm is high, and a conversation with your occupational health provider about retesting and risk assessment is a reasonable path forward.

Why No TB Test Can Confirm Latent Infection Directly

Something worth understanding about all TB testing is that neither the blood test nor the skin test directly detects the TB bacterium. Both measure your immune system’s memory of TB exposure. A positive IGRA tells you that your T cells react to TB-specific proteins; it does not tell you whether live bacteria are still present in your body. This indirect approach is why no test for latent TB has perfect accuracy, and why the clinical context around the test always matters as much as the result itself.

Active TB, by contrast, can be confirmed more directly through sputum cultures, molecular tests, and imaging. The false-positive problem is largely a feature of latent TB testing, where the target is a sleeping immune memory rather than an active infection you can see under a microscope. Until a test exists that can directly detect dormant TB bacteria or reliably predict which latently infected people will progress to disease, false-positive results in low-risk populations will remain an inherent limitation of the screening approach. Researchers have estimated that a hypothetical test with higher predictive value for actual disease progression could dramatically reduce unnecessary treatments, but no such test is available yet.²

1
Annals of the American Thoracic Society. Cumulative False-Positive QuantiFERON-TB Interferon-γ Release Assay Results
2
PubMed Central. The health and economic benefits of tests that predict future progression to tuberculosis disease
3
PubMed Central. Implications of the impact of prevalence on test thresholds and outcomes: lessons from tuberculosis
4
Morbidity and Mortality Weekly Report. Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010
5
Scientific Reports. Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model
6
PubMed Central. False-Positive Tuberculin Skin Test Results Among Low-Risk Healthcare Workers Following Implementation of Fifty-Dose Vials of Purified Protein Derivative
7
PLOS ONE. A borderline range for Quantiferon Gold In-Tube results
8
PLOS ONE. Refining the diagnostic approach to latent tuberculosis Infection with Quantiferon gold plus: A retrospective analysis of borderline results
9
PLOS ONE. Performance and variability of QuantiFERON Gold Plus assay associated with phlebotomy type
10
Diagnostic Microbiology and Infectious Disease. False-positive QuantiFERON TB-Gold test due to Mycobacterium gordonae
11
PubMed Central. Diagnosis of latent tuberculosis: Can we do better?
12
Journal of Infection. Tuberculosis skin test, but not interferon-γ-releasing assays is affected by BCG vaccination in HIV patients
13
PubMed. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts
14
BMJ Global Health. A costing framework to compare tuberculosis infection tests
15
PubMed. False-positive Results of Quantiferon-Tb-Gold Assay in Children
16
Pediatrics. Tuberculosis Infection in Children and Adolescents: Testing and Treatment
17
PubMed. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
18
PubMed Central. Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
19
PubMed Central. Comparison of QuantiFERON-TB Gold Plus and T-SPOT.TB in the Diagnosis of Active Tuberculosis
20
PubMed Central. Comparison of diagnostic accuracy of QuantiFERON‐TB Gold Plus and T‐SPOT.TB in the diagnosis of active tuberculosis in febrile patients